

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on August 17, 2007.

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

INFORMATION DISCLOSURE  
STATEMENT

Examining Group 1614

Patent Application

Docket No. ISI-101

Serial No. 10/561,411

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1614  
Applicants : Andrew Bushell, Kathryn Wood, Mahzuz Karim, Vanessa Oliveira, Brigit Sawitzki  
Serial No. : 10/561,411  
Filed : December 19, 2005  
Conf. No. : 1086  
For : Suppression of Transplant Rejection

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98


Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

It is respectfully requested that the references cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that their consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Frank C. Eisenschenk". The signature is fluid and cursive, with the first name "Frank" being more legible than the last name.

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950  
Gainesville, FL 32614-2950

FCE/gyl/sl

Attachments: Form PTO/SB/08; copies of references cited therein.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/561,411
Filing Date	December 19, 2005
First Named Inventor	Andrew Bushell
Art Unit	1614
Examiner Name	
Attorney Docket Number	ISI-101

Sheet

1

of

2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1	WO 90/15152 A	12-13-1990	Cobbold <i>et al.</i>	All	
	F2	EP 0 240 344 A	10-07-1987	Wellcome Found	All	
	F3	WO 01/00679 A	01-04-2001	Iwakoshi <i>et al.</i>	All	
	F4	WO/ 01/68134 A	09-20-2001	Genetics Inst.	All	
	F5					
	F6					
	F7					

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/561,411
Filing Date	December 19, 2005
First Named Inventor	Andrew Bushell
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ISI-101

Sheet	2	of	2
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	TAYLOR, P. A. <i>et al.</i> "CD4 <sup>+</sup> CD25 <sup>+</sup> Immune Regulatory Cells are Required for Induction of Tolerance to Alloantigen Via Costimulatory Blockade", <i>J. Exp. Med.</i> , June 4, 2001, pp. 1311-1317, Vol. 193, No. 11.	
	R2	QIN, S. <i>et al.</i> "Induction of Tolerance in Peripheral T Cells with Monoclonal Antibodies", <i>European Journal of Immunology</i> , 1990, pp. 2737-2745, Vol. 20, No. 12.	
	R3	KINGSLEY, C. I. <i>et al.</i> "CD25 <sup>+</sup> CD4 <sup>+</sup> Regulatory T Cells Prevent Graft Rejection: CTLA-4- and IL-10-Dependent Immunoregulation of Alloresponses <sup>1</sup> ", <i>Journal of Immunology</i> , February 1, 2002, pp. 1080-1086, Vol. 168, No. 3.	
	R4	WALDMANN, H. <i>et al.</i> "How do Monoclonal Antibodies Induce Tolerance? A Role for Infectious Tolerance?", <i>Annual Review of Immunology</i> , 1998, pp. 619-644, Vol. 16.	
	R5	TAYLOR, P. A. <i>et al.</i> "The Infusion of Ex Vivo Activated and Expanded CD4 <sup>+</sup> CD25 <sup>+</sup> Immune Regulatory Cells Inhibits Graft-Versus-Host Disease Lethality", <i>Blood</i> , May 15, 2002, pp. 3493-3499, Vol. 99, No. 10.	
	R6	TAYLOR, P. A. <i>et al.</i> "Tolerance Induction of Alloreactive T Cells Via Ex Vivo Blockade of the CD40:CD40L Costimulatory Pathway Results in the Generation of a Potent Immune Regulatory Cell", <i>Blood</i> , June 15, 2002, pp. 4601-4609, Vol. 99, No. 12.	
	R7	FALCONE, M. <i>et al.</i> "A T helper cell 2 (Th2) Immune Response against Non-self Antigens Modifies the Cytokine Profile of Autoimmune T Cells and Protects against Experimental Allergic Encephalomyelitis" <i>J. Exp. Med.</i> , March 3, 1997, pp. 901-907, Vol. 184, No. 5.	
	R8	BENJAMIN, R.J. <i>et al.</i> "Induction of tolerance by monoclonal antibody therapy" <i>Nature</i> , April 3, 1986, pp. 449-551, Vol. 320.	
	R9		
	R10		
	R11		
	R12		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.